Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab Long-term Extension Study in Atopic Dermatitis
NCT05916365Phase 3Completed
- Sponsor
- Almirall
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Started May 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05916365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916365.